Table 1.
Baseline clinical and biomarker characteristics
| No tafamidis | Tafamidis | P-value | |
|---|---|---|---|
| (n = 22) | (n = 23) | ||
| Age at baseline echo (years) | 78.24 (±6.67) | 79.13 (±6.00) | 0.64 |
| Male | 20 (91%) | 23 (100%) | 0.14 |
| BSA (m2) | 1.93 (±0.20) | 1.93 (±0.16) | 0.85 |
| Wild type ATTR | 21 (95%) | 21 (91%) | 0.58 |
| NAC Stage | |||
| I | 9 (41%) | 8 (35%) | 0.57 |
| II | 5 (23%) | 6 (26%) | 0.87 |
| III | 4 (18%) | 7 (30%) | 0.39 |
| Systolic blood pressure | 120 (29) | 121 (24) | 0.84 |
| Diastolic blood pressure | 70 (12) | 68 (19) | 0.64 |
| Atrial fibrillation or flutter at baseline echocardiogram | 9 (41%) | 10 (43%) | 0.56 |
| Myocardial infarction | 3 (14%) | 4 (17%) | 0.78 |
| Cardiac device | 6 (27%) | 8 (35%) | 0.32 |
| Dual chamber pacemaker | 1 (5%) | 4 (17%) | 0.17 |
| CRT-P | 2 (9%) | 2 (9%) | 0.96 |
| ICD | 1 (5%) | 0 | 0.30 |
| CRT-D | 1 (5%) | 1 (4%) | 0.97 |
| His bundle pacing | 0 | 1 (4%) | 0.32 |
| NTproBNP (ng/L) | 2807 (3599) | 2607 (5331) | 0.83 |
| Creatinine (mg/dL) | 1.33 (0.57) | 1.32 (0.81) | 0.40 |
| BUN | 29.25 (±15.18) | 29.62 (±14.78) | 0.94 |
| eGFR (mL/min/1.37 m2) | 52.78 (31.76) | 52.10 (37.18) | 0.36 |
| ACEi/ARB | 6 (27%) | 5 (22%) | 0.54 |
| Beta blocker | 12 (55%) | 9 (39%) | 0.17 |
| MRA | 6 (27%) | 6 (26%) | 0.78 |
Values are frequency (percentage), median (inter-quartile range), or mean (± standard deviation).